<DOC>
	<DOCNO>NCT01176851</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics , absolute bioavailability lung bioavailability inhale Glyco pMDI .</brief_summary>
	<brief_title>Biopharmaceutical Study Glyco pMDI With Without Charcoal Block v IV Bolus Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>1 . Males females healthy volunteer age 1865 year ; 2 . Written inform consent obtain first trial related activity . 3 . Able understand study procedure , risk involve ability train use device correctly . 4 . Body Mass Index ( BMI ) 18.0 32.0 kg/m2 ; 5 . Non exsmokers smoke &lt; 5 pack year ; 6 . Good physical mental status ; 7 . Normal blood pressure heart rate ; 8 . Electrocardiogram ( ECG ) consider normal ; 9 . Results laboratory test within normal range . 10 . Lung function measurement within normal range . 1 . Blood donation ( equal 450 ml ) blood loss le 8 week inhalation study medication ; 2 . Pregnant lactate woman woman childbearing potential , UNLESS use one acceptable method contraception . Male subject willing use acceptable method contraception . 3 . Positive HIV1 HIV2 serology ; 4 . Positive result Hepatitis serology indicate acute chronic Hepatitis B Hepatitis C ; 5 . Unsuitable vein repeat venipuncture ; 6 . History substance abuse drug abuse within 12 month prior screen visit positive urine drug screen screen ; 7 . Clinically relevant abnormal laboratory value suggest unknown disease require clinical investigation ; 8 . Clinically significant uncontrolled cardiac , hepatic , renal , gastrointestinal , endocrine , metabolic , neurologic , psychiatric disorder may interfere successful completion protocol ; 9 . Participation another clinical trial le 8 week prior inhalation study medication ; participation another clinical trial use radioactive material within 1 calendar year ; 10 . History hypersensitivity M3 Antagonists excipients contain formulation use trial ; 11 . Any drug treatment , include prescribed OTC medicine well vitamin , homeopathic remedy etc , take 14 day ( 2 month enzymeinducing enzymeinhibiting drug e.g. , glucocorticoid , phenobarbital , isoniazid ) precede first intake study drug , exception occasional paracetamol ( maximum 2 g per day maximum 10 g per 14 day mild nonexcluding condition ) . 12 . Treatment within previous 3 month drug know well define potential hepatotoxicity ( e.g . isoniazide , nimesulide , ketoconazole ) . 13 . Subjects refuse abstain alcohol caffeine contain food beverage grapefruit contain food beverages 48 hour prior first intake study medication entire duration study . 14 . Heavy caffeine drinker .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>None ( study healthy volunteer )</keyword>
</DOC>